Review
Biotechnology & Applied Microbiology
Theodoros Michelakos, Filippos Kontos, Omar Barakat, Luke Maggs, Joseph H. Schwab, Cristina R. Ferrone, Soldano Ferrone
Summary: Recent advances in immuno-oncology and bioengineering have sparked renewed interest in monoclonal antibody (mAb)-based immunotherapies for malignancies. A crucial factor for success in this area is the identification of tumor antigens (TAs) that can be targeted, with B7-H3 being one such TA. Despite unclear functions and receptors, B7-H3 is known to have a predominantly pro-tumorigenic effect by inhibiting the anti-tumor functions of T-cells. This review provides an overview of historical perspectives on TA-specific antibodies, discusses the criteria for attractive antibody-based immunotherapy targets, and highlights the potential of B7-H3 as a target for mAb-based cancer immunotherapy.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2021)
Review
Pharmacology & Pharmacy
Claudia Ceci, Pedro Miguel Lacal, Grazia Graziani
Summary: Antibody-drug conjugates (ADCs) are a new group of anticancer agents that combine the selectivity of monoclonal antibodies with the cell killing properties of chemotherapeutic agents. However, the development of ADCs faces challenges such as low tumor selectivity, premature release of drugs, and tumor resistance mechanisms. The design of inert antibodies and the discovery of innovative targets and drugs have led to the development of next-generation ADCs with improved therapeutic properties.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Engineering, Biomedical
Bo Wang, Ying Huang
Summary: Research has shown that modified gold nanoparticles can target M2 macrophages and achieve anti-tumor effects by killing M2 macrophages in vitro and in vivo under near-infrared laser irradiation.
LASERS IN MEDICAL SCIENCE
(2022)
Review
Immunology
Xiaojing Yang, Hanru Ren, Zhen Li, Xue Peng, Jie Fu
Summary: This article summarizes the application of immunotherapy in NPC, with a focus on the use of immunotherapy and radiotherapy in the treatment of NPC.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Kexin Li, Huan Yu, Zhihong Bao, Lu Xu, Hong Zhang, Tian Wang, Longyue Yu, Yue Yuan
Summary: The combination of photodynamic therapy and immunotherapy as a new antitumor strategy can improve the effectiveness of tumor treatment by increasing drug concentration, killing tumor cells, promoting immune response, and blocking immune checkpoint pathways.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2022)
Article
Oncology
Pierre -Florent Petit, Raphaele Bombart, Pierre -Hubert Desimpel, Stefan Naulaerts, Laurie Thouvenel, Jean-Francois Collet, Benoit J. Eynde, Jingjing Zhu
Summary: The delivery of anti-PD-L1 nanobody through tumor-targeting T cells shows promise in overcoming the limitations of immunotherapy based on PD-L1-specific antibodies.
CANCER IMMUNOLOGY RESEARCH
(2022)
Article
Oncology
Kwong Y. Tsang, Massimo Fantini, Anjum Zaki, Sharon A. Mavroukakis, Maria Pia Morelli, Christina M. Annunziata, Philip M. Arlen
Summary: Glycosylation is an important post-translational modification that occurs on mammalian proteins and lipids. Disruption of O-glycosylation patterns, especially the truncation of O-glycans, has been observed in cancer cells. Monoclonal antibodies targeting truncated O-glycans in cancer cells can be an effective strategy to counter tumor growth.
Review
Oncology
Andrew B. Katims, Peter A. Reisz, Lucas Nogueira, Hong Truong, Andrew T. Lenis, Eugene J. Pietzak, Kwanghee Kim, Jonathan A. Coleman
Summary: Urothelial carcinoma is a malignancy with poor prognosis. The standard treatment is chemotherapy followed by immunotherapy, but the survival outcomes are still unsatisfactory. New targeted therapies have been identified and shown efficacy as second-line treatment, which can be extended to other treatment categories.
Review
Health Care Sciences & Services
Sean Harrop, Chathuri Abeyakoon, Carrie Van der Weyden, H. Miles Prince
Summary: T-cell lymphomas, rare and unsatisfactorily treated, have shown progress in targeted therapies due to advancements in understanding T-cell lymphogenesis pathways and identifying therapeutic targets. New treatments include antibody-based, small molecule inhibitors, and immune-based therapies.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Oncology
Reza Mahmoudi, Hassan Dianat-Moghadam, Mansour Poorebrahim, Samaneh Siapoush, Vahdat Poortahmasebi, Reza Salahlou, Mohammad Rahmati
Summary: HER2-based immunotoxins are targeted therapies for human cancer, but further progress is needed in clinical settings.
CANCER CELL INTERNATIONAL
(2021)
Review
Biochemistry & Molecular Biology
Ayuob Aghanejad, Samad Farashi Bonab, Maryam Sepehri, Fatemeh Sadat Haghighi, Ali Tarighatnia, Christopher Kreiter, Nader D. Nader, Mohammad Reza Tohidkia
Summary: Monoclonal antibodies have been considered a promising tool in cancer therapy and the study of the tumor microenvironment has become increasingly important. Innovative strategies targeting the vasculature system, immune system, stroma-based growth signals, and cancer stem cells have been highlighted as ways to indirectly destroy tumor cells.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2022)
Article
Chemistry, Multidisciplinary
Si-jie Dai, Yu-ying Shao, Yang Zheng, Jin-yi Sun, Zhi-sheng Li, Jia-ying Shi, Meng-qi Yan, Xiao-yun Qiu, Ceng-lin Xu, Wan-sang Cho, Masahiro Nishibori, Sihyeong Yi, Seung Bum Park, Yi Wang, Zhong Chen
Summary: The study evaluated the therapeutic potential of inflachromene (ICM), a small-molecule inhibitor targeting HMGB1, in mouse epilepsy models. Results showed that ICM pretreatment significantly reduced the severity of epileptic seizures, indicating its potential as an anti-seizure drug.
ACTA PHARMACOLOGICA SINICA
(2023)
Review
Health Care Sciences & Services
Christopher Chang-Yew Leow, Michael Sze Yuan Low
Summary: Despite advancements in therapies such as proteasome inhibitors and immunomodulatory drugs, multiple myeloma remains a challenging and relapsing disease with no cure in sight. Over the past decade, novel drugs targeting essential cellular proteins and anti-apoptotic, ribosomal, and nuclear export proteins have emerged as potential treatments against malignant plasma cells.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Oncology
Ling Wang, Shixu Li, Jun Mei, Lin Ye
Summary: Retinoblastoma is the most common intraocular tumor in children. Chemotherapy is the main method of treatment currently, but immunotherapy has become a new strategy. This article summarizes several potential targets for retinoblastoma immunotherapy and discusses the corresponding techniques and feasibility.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Weiling Li, Xiaoling Zhang, Yunyi Du, Ying Zhang, Jing Lu, Wenqing Hu, Jun Zhao
Summary: The incidence of gastric/gastroesophageal junction (G/GEJ) cancer remains high globally, especially in China. Patients with early-stage G/GEJ adenocarcinoma have a better prognosis after surgery, while those with advanced metastatic G/GEJ adenocarcinoma have a less optimistic long-term survival outlook. The identification of various biomarkers, particularly microsatellite instability (MSI), programmed cell death-ligand 1 (PD-L1), human epidermal growth factor receptor 2 (HER2), tumor mutational burden (TMB), and Epstein-Barr virus (EBV), has significantly improved the clinical efficacy of treatments for G/GEJ adenocarcinoma by identifying targeted populations. HER2-targeted therapy has shown excellent clinical outcomes for patients with advanced HER2-positive G/GEJ adenocarcinoma, although some patients develop resistance.
BIOMARKER RESEARCH
(2022)
Article
Biotechnology & Applied Microbiology
Sara Stigliani, Michela Croce, Fabio Morandi, Paola Scaruffi, Valentina Rigo, Barbara Carlini, Carla Manzitti, Anna Rita Gigliotti, Gian Paolo Tonini, Vito Pistoia, Silvano Ferrini, Maria Valeria Corrias
BIOMED RESEARCH INTERNATIONAL
(2015)
Article
Immunology
Fabio Morandi, Michela Croce, Giuliana Cangemi, Sebastiano Barco, Valentina Rigo, Barbara Carlini, Loredana Amoroso, Vito Pistoia, Silvano Ferrini, Maria Valeria Corrias
JOURNAL OF IMMUNOLOGY RESEARCH
(2015)
Article
Immunology
Fabio Morandi, Sarah Pozzi, Barbara Carlini, Loredana Amoroso, Vito Pistoia, Maria Valeria Corrias
JOURNAL OF IMMUNOLOGY RESEARCH
(2016)
